Aim: This study aims to evaluate the dual benefits of dulaglutide in improving glycemic control and reducing knee OA pain.Patients & methods: Elderly T2DM patients diagnosed with bilateral knee OA on conventional OA treatment for at least 3 months were studied for their glycemic metrics, OA pain scores and NSAID consumption at baseline, 3 months and 6 months.Results: Significant improvements in glycemic control were observed, HbA1c decreased from 8.7% to 6.5% over 6 months. Pain scores, NSAID, body weight and BMI showed substantial reductions over time. Positive correlation (r = 0.73, p < 0.001) was found between glycemic control and pain reduction.Conclusion: Dulaglutide improves glycemic control, knee joint OA pain and weight management in elderly patients with T2DM.
Keywords: dulaglutide; elderly patients; glycemic control; knee osteoarthritis; type 2 diabetes mellitus.
What is this article about? We looked into how well dulaglutide works to both control blood sugar and reduce knee pain in people with type 2 Diabetes and osteoarthritis. This could be a useful treatment for older patients dealing with both conditions.What were the results? The most relevant findings were:Better Blood Sugar Control: After using dulaglutide for three and 6 months, there were noticeable improvements in blood sugar levels.Less Knee Pain: People experienced less knee pain from osteoarthritis and used fewer painkillers.Weight Loss: The average body weight and body mass index (BMI) decreased with this treatment.Pain Relief Linked to Better Blood Sugar: As blood sugar levels improved, knee pain from osteoarthritis also lessened.What do the results of the study mean? The results showed that elderly T2DM patients prescribed with dulaglutide would be able to achieve improved glycemic control, knee joint OA pain and weight management.